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Periventricular white matter hyperintensities (pvWMHs) are a neurological feature 
detected with magnetic resonance imaging (MRI) and are clinically associated with an 
increased risk of stroke and dementia. pvWMHs are characterized by white matter lesions 
with myelin and axon rarefaction, and as such likely involve changes in lipid composition, 
however these alterations remain unknown. Lipids are critical in determining cell function 
and survival, although their detection within tissue, until recently has been challenging. 
Perturbations in lipid expression have previously been associated with neurological 
disorders. Matrix-assisted laser desorption/ionization (MALDI) imaging mass 
spectrometry (IMS) is an emerging technique for untargeted, high-throughput 
investigation of lipid expression and spatial distribution in situ, however the use of MALDI 
IMS has been previously been limited by the need for non-embedded, non-fixed, fresh-
frozen samples. Work within this thesis demonstrates the novel use of MALDI IMS to 
distinguish regional lipid abnormalities that correlate with MRI defined pvWMHs within 
ammonium formate washed, formalin-fixed human archival samples. MALDI IMS scans 
were conducted in positive or negative ion detection mode on tissue sublimated with 2,5-
dihydroxybenzoic acid or 1,5- diaminonaphthalene matrices, respectively. Using a broad, 
untargeted approach to lipid analysis we consistently detected 116 lipid ion species in 21 
tissue blocks from 11 different post-mortem formalin-fixed human brains. Comparing the 
monoisotopic mass peaks of these lipid ions elucidated significant differences in lipid 
expression between pvWMHs and NAWM for 31 lipid ion species. Expanding our 
understanding of alterations in lipid composition will provide greater knowledge of 
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molecular mechanisms underpinning ischemic white matter lesions and provides the 
potential for novel therapeutic interventions targeting lipid composition abnormalities. 
Keywords: CNS, MRI, pvWMHs, neurodegeneration, MALDI TOF IMS, lipids, 
lipidomics, multimodal imaging 
 
SUMMARY FOR LAY AUDIENCE 
 Diseases of the brain, such as Alzheimer’s disease and stroke, represent a major 
cause of disability and death, yet many remain uncurable. This is partly due to a limited 
understanding of molecular changes that underlie diseases. Of the three categories of 
biological macromolecules, which are proteins, lipids, and carbohydrates, lipids are the 
most abundant in the brain, accounting for 60% of the dried mass. These lipids contribute 
to numerous aspects of cells in the brain including forming the structural walls of cells and 
influencing the behaviour of cells. Due to the abundance of lipids in the brain and their 
ability to influence cells, they are particularly likely to be altered in diseases of the brain. 
Previous studies have demonstrated that changes in lipids are part of many diseases of 
the brain, but our understanding still remains limited. This limited understanding is 
partially due to the difficulty of studying the enormous variety of lipids that occur in the 
brain. Recent improvements in mass spectrometry, a technique for studying lipids, have 
opened a door for investigating changes in lipids within diseased brains. In this thesis, we 
use this technique to identify lipid abnormalities within diseased post-mortem human 
brains. By doing so, we aim to establish a workflow that will allow others to study changes 
in lipids that are associated with clinically observable diseases. Research into these lipid 
changes may identify therapeutic targets to help manage or cure neurological diseases.  
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CHAPTER 1: INTRODUCTION 
1.1. The Brain and Neurodegeneration 
 The central nervous system (CNS) is responsible for an impressive array of tasks 
including receiving sensory input, providing motor output, and cognition. The two major 
components of the CNS are the grey matter, which primarily contains neuronal cell bodies 
and functions to permit the aforementioned tasks, and the white matter, which is made 
up of long myelinated neuronal axons and functions to provide communication between 
grey matter regions and the body. Grey matter and white matter are mutually dependent 
for proper function, and as such, deterioration of either can result in a myriad of clinical 
outcomes including chronic disability, decreased quality of life, and death. The societal 
and economic impacts of CNS diseases cannot be understated as the chronic morbidity 
of CNS diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), 
means that patients will often require decades of expensive care. Worse yet, morbidity 
and mortality caused by neurodegenerative diseases will continue to increase with aging 
populations around the world1. For example, AD alone costs an estimated 1% of global 
GDP and the cost of care is only projected to increase as the global prevalence of AD 
patients is estimated to surpass 100 million by 20502,3. The severe impacts of CNS 
diseases, for both the patient and society, makes the research of disease etiology, 
progression, and treatment imperative to mitigate the impact of CNS diseases. 
1.1.2 Neuroimaging 
 Clinical neuroimaging modalities, such as magnetic resonance imaging (MRI), 
positron emission tomography (PET), and computed tomography (CT), are invaluable 
resources for detecting and monitoring CNS disease and injury. MRI is the most 
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frequently used clinical imaging modality of the CNS and can detect structural 
abnormalities associated with CNS injury, white matter deterioration, and ischemic events 
such as stroke4,5. Different MRI pulse sequences, most commonly T1 and T2, can be 
used to alter the visualization of different structures. T2 MRI produces high signal intensity 
for grey matter and cerebrospinal fluid (CSF), while white matter appears relatively 
hypointense. T2 MRI combined with fluid-attenuated inversion recovery (FLAIR) is 
commonly used for neuroimaging of white matter pathologies as FLAIR suppresses the 
hyperintense signal of CSF thus easing the detection of periventricular white matter  
abnormalities6. Whilst MRI is useful for the detection of CNS diseases in clinical patients, 
thorough multimodal investigation of MRI-defined post-mortem samples is required for a 
greater understanding of the molecular mechanisms underlying clinically observable 
pathologies4. 
1.2. White Matter Hyperintensities 
White matter hyperintensities (WMHs) are an early clinical feature of white matter 
degeneration that can be detected with T2-weighted FLAIR MRI7–9. Historically 
overlooked as an inevitable feature of ‘normal aging’, recent studies have demonstrated 
that WMHs are significantly associated with health risk factors and neurodegeneration10–
12. These WMHs are clinically associated with a 3-fold increased risk of stroke and 2-fold 
increased risk of dementia10. Furthermore, WMHs may contribute to an accelerated rate 
of global cognitive decline, independent of other neurodegenerative disorders or injury10. 
WMHs are named due to the region appearing bright on MRI relative to the darker signal 
typically associated with white matter, a change that is attributed to the occurrence of 
localized edema within the tissue13. WMHs are heterogenous in etiology, however, 
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periventricular WMHs (pvWMHs) are believed to occur in part due to cerebral small vessel 
disease causing vascular hypoperfusion of the periventricular region resulting in a white 
matter lesion14–17. pvWMHs may be observed to be progressive in routine MRI of patients, 
a feature associated with a worse neurological prognosis18,19. Histological analysis of 
deteriorated white matter was required to enhance our understanding of the clinically 
observable feature, however this analysis was delayed due to limitations in detecting 
white matter deterioration in post-mortem MRI20,21. This technical limitation has been 
ameliorated by improvements in our understanding of MRI signals from formalin-fixed 
post-mortem samples to the point that post-mortem MRI is now considered to be suitable 
for designating the spatial extent and severity of WMHs20. 
Numerous studies using post-mortem histopathological analysis of pvWMHs have 
shown rarefaction of both axons and myelin, as well as an increase of microgliosis and 
astrocytosis13,21,22. Whilst the loss of myelin alone undoubtedly suggests an alteration in 
the lipid content of these regions, very little is known about specific alterations in the 
molecular and lipid composition of the tissue underlying pvWMHs. This gap in knowledge 
is, in part, due to a lack of techniques available for profiling the lipid composition of 
formalin-fixed post-mortem human brain tissue with adequate sensitivity to resolve 
differences in the lipid composition of pvWMHs relative to adjacent normal-appearing 
white matter (NAWM). 
1.3 Lipids 
Lipids are biological macromolecules that are critical to the function and survival of 
every cell, but are particularly important for proper function of the CNS. Lipids have 
incredibly diverse roles, from being constitutive molecules of cell membranes, acting as 
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energy reservoirs, interacting with a plethora of associated biomolecules to influence their 
function, and serving as secondary messengers in key cell signalling pathways23,24. The 
functional diversity of lipids is accompanied and accommodated by an even greater 
diversity in lipid molecular structures, which influence the chemical, physical, and 
biological properties of lipids24,25. This structural and functional heterogeneity contributes 
to the difficulty of studying lipid expression and distribution within complex heterogenous 
mixtures, such as human brain tissue, a factor which has delayed our understanding of 
lipid function. Our understanding of lipid function, while still incomplete, is expanding 
through the use of multimodal investigations into the diverse mechanisms by which lipids 
influence cells26–28. The technical difficulty of studying lipids within intact biological tissue, 
has ameliorated with developments in lipid detection techniques, notable imaging mass 
spectrometry (IMS)29,30. Taken together, the critical biological importance of lipids, the 
historical difficulty of lipid research, and recent advancements in techniques for the study 
of lipids, have resulted in a unique opportunity to expand our understanding of this 
understudied trove of biological information. 
1.3.1 Lipids in Cell Membranes 
 The plasma membrane is a dynamic heterogenous bilayer that surrounds 
every cell, compartmentalizing them from their environment. These membranes were 
often erroneously characterized from a protein-centric view to be relatively passive barrier 
that serves to control the flow of molecules and contain the more biologically exciting 
membrane-proteins31. It is becoming increasing recognized that these membranes are 
heterogeneously composed of diverse lipid species which dramatically influence the 
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function of the membrane they create, membrane-associated proteins, and the cell as a 
whole24. 
Our understanding of the complexities and roles of cell membranes has greatly 
expanded in recent decades. Currently it is recognized that, beside their barrier function, 
cell membranes are involved in the organization and regulation of numerous cell 
signalling pathways23,32. This organization and regulation can occur via membrane 
microdomains, previously referred to as lipid rafts, which are small (10-200 nm) regions 
of the membrane that are heterogeneously enriched in proteins, sphingolipids such as 
gangliosides, and cholesterol33–35. Membrane microdomains are known to undergo 
dynamic changes in response to the internal conditions and external environment of the 
cell34,35. Interestingly, the lipid component of these membrane microdomains are believed 
to be potent modulators of the protein composition and signalling pathways associated 
with these microdomains, such as, ganglioside-mediated regulation of the tyrosine 
receptor kinase A (TrkA) pro-survival pathway36,37. The molecular mechanisms by which 
lipids influence signaling depending on the pathway in question but include lipid-mediated 
recruitment of proteins to membrane microdomains and non-covalent lipid-protein binding 
to alter protein activity38. The influence of lipids on protein activity can be exemplified by 
the ability of specific gangliosides to enhance the activation of the aforementioned TrkA 
pro-survival pathway, a phenomenon which will be further discussed later in this 
introduction. 
1.3.2 Functions – Structural 
The plasma membrane is a complex 3D structure that features incredible 
biophysical and compositional heterogeneity. It is now known that this heterogeneity, 
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which occurs both laterally and between leaflets of the bilayer, is not a random 
phenomenon but rather a complex biophysical system with profound physiological 
relevance37. Alterations in physical membrane properties have been demonstrated 
influence the activity of transmembrane proteins and peripheral membrane binding 
proteins which in-turn affect intracellular signalling pathways23,24. These physical 
alterations can be caused by variations in the molecular structures of acyl chains and 
head groups of lipids. Alterations in these lipid structures influence the physical 
parameters of the membrane including width, fluidity, and curvature. For example, 
different lengths and saturations of the acyl chain influence bilayer width, with a longer 
chain promoting a wider bilayer width24,39. According to the widely supported ‘hydrophobic 
mismatch hypothesis’, this bilayer width subsequently influences the localization and 
activity of transmembrane proteins based on the width of their hydrophobic, 
transmembrane domain (Fig 1A)39,40.  
The tight packing of amphipathic lipids to form a lipid bilayer is an energetic 
compromise between the hydrophilic and hydrophobic domains, where neither domain 
exists at the lower energy state they would assume when independent from the other23. 
As such, the lipid bilayer exists as a stable yet highly ordered, high-energy structure. This 
is driven, in part, by the energetically-favourable association of hydrophilic tails with 
adjacent tails and results in the crowding of headgroups at the surfaces of the bilayer. 
The crowding of headgroups means that the structural diversity of headgroups present 
must be carefully considered when conceptualizing the physical structure of lipid bilayers, 
as these hydrophilic domains are constantly influencing the adjacent heads with physical 
and ionic interactions23,24. This is demonstrated by the tendency of lipids that contain a 
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large head group, such as glycosphingolipids, to induce spontaneous positive curvature 
of a lipid membrane (Fig 1B)41. Vice-versa, lipids with a small hydrophilic head, such as 
PE, tend to induce negative curvature (Fig 1B)42. When visualized as a bilayer, the 
asymmetric distribution of a large headgroup lipid to the outer leaflet and a small 
headgroup lipid to the inner leaflet would promote intracellular curvature (Fig 1C). The 
biological relevance of this curvature is demonstrated by the necessity of localized lipid-
deacetylation/acetylation enzymes to facilitate golgi membrane fission and other lipid-
regulated membrane deformation events41,43. While our current understanding of lipid 
diversity and how it influences the biophysical properties of membranes remains 
incomplete, lipids play a critical and often understated role in cell function. Continued 
investigation of lipids and how they influence cell function will undoubtedly assist our 
understanding and treatment of CNS conditions that include a lipid abnormality 
component. 
 
Figure 1. Select examples of the biophysical influence of lipids on lipid membranes. 
A) Alterations in the length of the hydrophobic tail, influences the width of the hydrophobic 
region of a lipid bilayer. The alterations in-turn influences the localization of 
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transmembrane proteins relative to the width of their transmembrane domain. B) The 
physical structure of the head, and its ratio to tail width, influences lipid membrane 
curvature. The inverted-cone shape induces spontaneous positive curvature of the 
membrane. Conical lipids, those with a head width that is narrower than the tail width, 
induce spontaneous negative curvature of the membrane. C) Asymmetrical bilayer 
distribution of a conical and inverted-conical lipids can synergistically promote bilayer 
curvature. Created with Biorender.com. 
1.3.3 Functions – Signalling 
The mechanisms by which lipids influence cell signalling pathways are multifaceted, 
a diversity which is required to accommodate the diversity of pathways that are 
influenced24. This diversity, along with the technical difficulties associated with lipid 
investigation, has impeded our understanding of the mechanisms and functions of 
specific lipids. Distinguishing the structural and signalling aspects of lipids can be 
convoluted as lipids can affect signalling indirectly by influencing the physical parameters 
of the plasma membrane, in-turn influencing membrane-associated signalling pathways. 
Since some of these structural contributions were previously discussed, this section will 
instead provide examples of signalling that aren’t associated with structural functions, and 
one interesting example of a structurally-mediated signalling pathway.  
One of the most widely known lipid signalling events is the involvement of 
phosphatidylinositol 4,5-biphosphate (PIP2) for the transduction and amplification of 
certain G-protein couple receptor pathways44,45. In this pathway, the protein 
phospholipase C hydrolytically cleaves the head and tail of PIP2 into the secondary 
messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)45. The tail, DAG, 
remains embedded in the inner leaflet of the plasma membrane and goes on to activate 
members of the protein kinase C family which induce a myriad of downstream effects 
including proliferation and differentiation46,47. Meanwhile the head, IP3, now liberated from 
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the membrane can diffuse through the cytoplasm and interact with it’s own set of 
associated pathways, primarily activating channels that induce intracellular release of 
Ca2+45,48. While the downstream signals of DAG and IP3 can vary depending on cell 
population and environmental effects, it is clear that these lipid-mediated signalling 
pathways are essential for proper cell regulation48. This is emphasized by the presence 
of aberrant PIP2-associated signalling in pathologies such as cancers and AD48. In AD, it 
has been demonstrated that beta-amyloid 42 (Aβ42) oligomers associated with AD can 
induce intracellular release of Ca2+, which according to the calcium hypothesis of AD is a 
cytotoxic insult that may contribute to AD pathology49,50. This release is believed to be 
mediated by IP3, as pre-treatment with IP3 receptor antagonists attenuates Ca2+ release50. 
Interestingly, mass spectrometry (MS) has been used for the detection of PI species, 
including PIP251,52. As such, using MS to investigate lipids within pathological tissues may 
elucidate aberrant PIP2 signalling if PIP2 levels were found to be altered within a sample52. 
An interesting structurally-mediated signalling pathway is that of the sphingolipid 
monosialotetrahexosylganglioside (GM1) and tyrosine receptor kinase A (TrkA). GM1 has 
been demonstrated to have neurotrophic effects on mature neurons, however the 
mechanisms for this are uncertain and potentially multimodal53–55. One pathway that has 
been implicated is the TrkA neuronal pro-survival pathway53. A current theory postulates 
that GM1 plays an organizational role, where increased GM1 in the outer leaflet of a 
plasma membrane encourages the co-localization of TrkA receptors due to interactions 
between the extracellular carbohydrate moiety of GM1 and extracellular domains of 
TrkA56. TrkA receptors require dimerization for activation, so increased TrkA receptor 
localization enhances the opportunity for TrkA receptor activation without an increase in 
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Trk ligands53. As such, the organizational properties of lipids such as GM1 may serve as 
potentiators for associated signalling pathways. Numerous studies have demonstrated 
robust in situ detection of GM1, and associated gangliosides, from brain tissue samples 
using MS57,58. Thus, MS may be able to distinguish ganglioside abnormalities in 
pathologies, if they exist, which has the potential to guide future investigation of pathways 
associated with lipid abnormalities and how they relate to the pathology. 
1.3.4 The involvement of lipids in diseases of the CNS 
 The abundance of lipids in the brain, as well as, the aforementioned roles of lipids 
and lipid metabolites in cell function, means that diseases of the CNS are uniquely prone 
to have a lipid perturbation component59. This is supported by the growing recognition of 
lipid dyshomeostasis associated with stroke, multiple sclerosis, AD, and Huntington’s 
disease59–62. Although some observational studies previously attributed lipids 
abnormalities to be end-product alterations associated with the disease, recent 
experimental approaches have demonstrated an active role of altered lipids in mediating 
disease progression62,63. Lipid dyshomeostasis may play a key role in additional diseases 
of the CNS, however, elucidation of lipid abnormalities has been stymied due to the 
technical difficulty of specifically and sensitively resolving lipid abnormalities associated 
with CNS diseases64. Furthermore, detection and quantification of lipids while retaining 
spatial distribution information was historically impossible due to the reliance on 
techniques that required tissue homogenization64. Additionally, tissue homogenization 
results in the loss of information on lipid alterations that may be specific to distinct cell 
populations confounding the results of techniques that require homogenization. 
Expanding our knowledge of lipid abnormalities associated with CNS diseases would 
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enhance our understanding of potential molecular mechanisms contributing to disease 
progression, and provide the opportunity for novel lipid-targeting therapeutics59. 
1.4 Mass Spectrometry 
MS is a semi-quantitative analytical technique by which a wide variety of molecules such 
as proteins, lipids, or metabolites in a sample can be detected65,66. In general, an MS 
instrument has three key components, an ion source responsible for the generation of 
ions from a sample, a mass analyzer which separates ions by their mass-to-charge ratio 
(m/z), and a detector for the subsequent detection of each ion species to generate a mass 
spectrum67. A mass spectrum is an output plot displaying relative ion quantity, known as 
intensity, on the y-axis with a continuous m/z range on the x-axis67. This versatile 
technique permits the simultaneous detection and quantification of a multitude of 
ionizable molecules, and as such, research has just begun to scratch the surface of the 
questions which MS can be used to investigate. 
1.4.1 Imaging mass spectrometry 
IMS is currently the only technique that permits simultaneous in situ detection, 
quantification, and visualization of multiple small molecules, such as lipid species, within 
a single tissue section30,66. IMS functions identically to the mechanism of MS, but the 
process is repeated in a stepwise manner to generate individual mass spectra for each 
point on the tissue68. This results in the generation of voxels of data, where every pixel in 
an intensity map of the tissue has an entire mass spectrum contained within it68. As such, 
IMS permits visualization and relative quantification of every detected ion in the mass 
spectra associated with the scanned sample68. The unique ability of IMS to 
12 
 
simultaneously detect, quantify, and visualize multiple ion species makes IMS an 
invaluable tool for lipidomic studies. 
1.4.2 MS Ion Sources 
 MS relies on the use of ions to separate molecules by their m/z and for their 
subsequent detection by an ion detector. To produce ions from the sample, MS 
instruments have a critical component referred to as the ‘ion source’. Whilst multiple ion 
sources exist, they are often categorized as ‘hard’ and ‘soft’ ionization techniques69. In 
brief, these ion sources differ in how they ionize molecules of interest, however, the 
differences in ionization influences which molecules are ionized and detected69. Hard 
ionization causes relatively large quantities of energy to be transferred from the ion source 
to the analyte molecules in the sample, a process which increases the opportunity for 
fragmentation to occur69. In contrast, soft ionization imparts minimal energy to the 
analytes and risks little to no fragmentation. While hard ionization sources, and the 
fragmentation that occurs, can be beneficial for analysis in chemically pure samples, 
fragmentation can confound the mass spectra generated from chemically heterogenous 
samples, such as tissue samples. For this reason, soft ion sources such as matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI) are often 
the preferred technique for tissue analysis69,70. As such, careful consideration and 
selection of an ion source is an important facet of planning any MS experiment. The 
following subsections will provide a brief discussion of ion sources in the context of 
lipidomic investigations. 
 An additional consideration regarding the detection of lipid ions in MS is that lipid 
ions display preferential negative or positive ionization depending on the composition of 
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their headgroup30. As a generalization, negative ion detection scans of human brain tissue 
tend to detect [M-H]- ions of phosphatidylethanolamines (PE), phosphatidylserines (PS), 
phosphatidylinositols (PI) and acidic sphingolipids30. In-contrast, positive ion detection 
spectra of brain tissue are dominated by sphingomyelins (SM) and phosphatidylcholines 
(PC), the latter of which are often detected in such abundance that the detection of other 
lipid species is suppressed30,71. This abundance of PC and SM species is due to their 
quaternary amine group which contains a permanent positive charge30. Whilst negative 
lipid ions tend to form as [M-H]-, positive lipid ions commonly form as [M+H]+, [M+Na]+, 
[M+K]+30. While these assumptions can help when beginning to interpret a MS dataset, it 
must also be considered that other ions exist, such as the dehydration of cholesterol to 
form the commonly detected m/z 369.3 [cholesterol-H2O]+ ion72. As such, the variety of 
possible ions must be careful considered when analyzing any dataset, a possibility which 
can be added by additional MS techniques discussed later. 
1.4.3 Ion sources - ESI 
 ESI has been used as a soft ion source for biomolecules since the 1980s, however, 
this technique has several limitations when working with complex heterogenous mixtures 
such as biological samples73,74. The process of ESI involves the introduction of a solvent, 
evaporation, and development of distinct gas-phase ions75. A key difference between 
MALDI and ESI is that the process of ionization in ESI occurs with a liquid-phase to gas-
phase transition, in contrast to the solid to gas-phase transition of MALDI. This 
requirement for a liquid-phase sample means that ESI is incompatible with IMS, as 
introduction of a solvent produces in homogenization and loss of spatial information prior 
to ionization. Additionally, ESI is susceptible to contamination from salts and other 
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endogenously occurring molecules in biological samples76. These contaminants must be 
separated from the sample using liquid chromatography prior to ionization. Lastly, ESI is 
prone to producing ions with multiple charges73. This phenomenon can be beneficial for 
the analysis of large biomolecules, such as proteins, as most MS instruments function 
best for the detection of molecules in the <1500 m/z range67. However, the majority of 
lipids already occur with a mass of <1500 Daltons and as such do not require multiple 
charges to be detected in the <1500 m/z range72. Furthermore, the addition of multiple 
charges risks a loss of mass resolution as each additional charge halves the m/z 
difference of ions of different masses. The limitations of ESI regarding analysis of 
biological samples, lipid detection, and incompatibility with IMS, necessitated the 
development of further soft ionization sources. 
1.4.4 Ion sources - MALDI 
MALDI is a commonly used ion source for lipidomic investigations due to its ‘soft 
ionization’ process, meaning that relatively little energy is imparted into the molecule to 
generate an ion. Soft ionization is essential for lipid detection experiments as it reduces 
the risk of fragmentation occurring, a process that can confound lipid studies as fragments 
of larger lipid species are often indistinguishable to intact molecules of smaller related 
lipids77. The soft ionization of MALDI is achieved by coating the sample with the desired 
matrix, which infiltrates the sample to form crystals around molecules and assists in the 
transfer of energy from a laser pulse to the molecules of interest78 (Fig 2). This laser pulse 
heats a localized spot to energetically excite the matrix, resulting in the molecules within 
undergoing a gas-phase transition and ionization. While the mechanism of ionization 
remains uncertain, the dominant theory is gas-phase ionization where the analyte 
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molecules are protonated or deprotonated by surrounding gas-phase matrix ions78,79. 
Depending on the matrix chosen MALDI can be suitable for the ionization and detection 
of a variety of biomolecules, including proteins, carbohydrates, and lipids80. Due to the 
diversity of molecules that can be detected, the reduced risk of delocalization, and the 
minimal fragmentation induced by soft ionization, MALDI was chosen as the ion source 
for the experiments discussed in this work. 
 
Figure 2. Schematic of the process of matrix deposition, desorption, and 
ionization in MALDI MS. Following matrix application, matrix molecules co-crystalize 
with analyte molecules. Upon laser ablation, the matrix assists the gentle transfer of heat 
energy from the laser to molecules within the sample. This energy permits the desorption 
transition into gas phase, as well as proton transfer to or from the analyte molecules to 
ionize them for subsequent TOF and detection. Created with Biorender.com. 
1.4.5 Limitations of MALDI 
Limitations of MALDI as an ion source include concerns about reproducibility due 
to heterogenous matrix application and the semi-quantitative nature of ion detection from 
a heterogenous sample30. Fortunately, both limitations can be ameliorated by 
methodology. Homogenous matrix application can be achieved by matrix 
sublimation/deposition, a process which involves heating a known mass of solid-phase 
matrix inside a vacuum chamber to induce sublimation, solid to gas-phase transition81. 
As the gas-phase matrix diffuses through the chamber it contacts the sample mounted to 
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a slide which has been conductively cooled by an ice slush chamber above. This 
temperature difference causes deposition, gas to solid-phase transition, homogenously 
across the sample. Although matrix application can be improved by the use of matrix 
sublimation, the semi-quantitative nature of MALDI MS, is far more difficult to overcome. 
Quantification limitations are due to spectrum saturation from the most prevalent ions and 
uncertainties in the mechanism of ionization for each matrix82. In a complex biological 
sample, it is unlikely that absolute quantification can ever confidently be achieved, as 
such, it is best to use MALDI IMS for relative intrasample comparison of detected ions, or 
inter-sample comparison of similar tissues that have been identically prepared. 
1.4.6 Mass analyzers 
 As previously mentioned, mass analyzers are a critical component of any MS 
instrument, responsible for the separation of ions by their m/z. While various mass 
analyzers exist, they typically function by using charged fields to control the movement of 
gas-phase ions produced from the sample. As with other facets of the MS instrument, 
selection of a mass analyzer should be unique to each experiment. This is due to 
differences in the three key characteristics of mass analyzers; mass accuracy, the 
accuracy of experimental m/z values to actual m/z values, mass resolution, the m/z limit 
at which the analyzer can distinguish two mass peaks, and mass range, the range, and 
limits of m/z values that an analyzer can be used for83. Commonly used mass analyzers 
include time-of-flight (TOF), quadrupole, and quadrupole ion trap. Detailed discussion of 
the types of mass analyzers and their mechanisms exceeds the scope of this introduction, 
but several in-depth reviews on the topic exist83,84.  
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1.4.7 Time-of-flight mass analyzers 
TOF is a commonly used mass analyzer due to its rapid mass spectrum acquisition 
speed, and high mass accuracy, mass resolution and mass range83. In a MALDI-TOF-
IMS instrument, TOF occurs following MALDI when analyte molecules have already 
undergone gas phase transition and ionization (Fig 3A). The analyte ions are passed 
through a series of magnetically charged gates causing them to accelerate through a 
flight tube. This flight tube serves to separate analyte ions based on both their mass and 
charge since heavier molecules will fly slower than lighter molecules of identical charge. 
At the end of the flight tube a detector measures both the time is takes for ions to arrive, 
which permits the assignment of m/z values to these ions, and the quantity of ions arriving 
at a given m/z, allowing the user to semi-quantitatively interpret the number of ions 
generated from a sample. Due to the benefits of TOF, such as rapid acquisition of broad 
mass spectra, TOF mass analyzers are particularly suited for lipidomic investigations. 
1.4.8 Ion identification and MALDI TOF/TOF tandem mass spectrometry 
 Ion identification is a necessary part of any MS experiment, and can be a 
particularly difficult task in untargeted, shotgun-style analysis of molecularly-complex 
samples such as human tissue30. Ion identities can be assigned by accurate mass, by 
which the experimental m/z value is compared to theoretical m/z values, however, this 
approach is limited by both the mass accuracy of the instrument and the inability to 
distinguish ions of identical m/z such as structural isomers which commonly occurs with 
lipids30,72. As such, tandem mass spectrometry (MS/MS) is the gold-standard for 
identification of ions detected in MS experiments30,72. MS/MS differs from standard MS 
by coupling two mass analyzers in sequence (Fig 3B). This permits the selection of ions 
detected at a specific m/z value in the first mass analyzer, annotated as MS1, causing all 
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other ions to be gated out of the second mass analyzer, MS2. Before the selected ions, 
known as precursor ions, reach MS2, they are subjected to fragmentation into product 
ions, which enables the production of a ‘fingerprint-like’ mass spectrum at MS2 based on 
the m/z of each product ion fragment. The product ion fragments that a molecule can 
produce are often predictable based on its molecular structure and its innate tendency to 
fragment at certain bonds85. A prime example of this is the tendency for the lipid head 
group, or a portion of it, to fragment away. This headgroup fragment alone can 
dramatically assist lipid identification by indicating the lipid class from which parent ion 
originated (Table 1). MS/MS is an invaluable identification technique for heterogenous 
samples that contain many distinct molecules occurring at similar m/z ranges, such as 





Figure 3. Schematic of mass analysis by TOF and TOF/TOF MSMS following MALDI. 
A) Following MALDI, gas phase ions are accelerated into a flight tube by a potential 
difference between the sample plate and a series of charged gates. Molecules of identical 
charge receive the same amount of kinetic energy, causing heavier molecules to fly 
slower than lighter molecules of the same charge. This separation of molecules based on 
their m/z as they move through the flight tube causes them to reach the detector at 
different times which assigns an m/z value to each molecule based on its relative arrival 
time. B) TOF/TOF MSMS is achieved by connecting two TOF mass analyzers in 
sequence. This permits the selection of molecules at a given m/z by gating other 
molecules out of the second analyzer. Selected molecules then undergo fragmentation, 
and the product ions of the precursor species are subjected to TOF and subsequent 











Table 1. Summary of characteristic lipid fragments observed in negative mode 
MSMS. Summary of characteristic lipid fragments previously observed in MSMS product 
ion spectra generated from lipids. Relevant citations for all ion species are in the main 
text. 
1.4.9. MALDI IMS of lipids 
Historically, technical limitations prevented detection and quantification of lipids 
while maintaining both spatial distribution and lipid species specificity. This is due to 
techniques relying on either immunohistochemistry, which maintains spatial distribution 
but loses specificity for the hydrophobic domain, or analysis of extracted homogenized 
tissue which causes loss of spatial distribution information72. Throughout the 1990s and 
2000s this barrier was breached by the application of MALDI IMS for in situ detection of 
biomolecules86,87. Since then, MALDI IMS has been applied for the detection of diverse 
lipid species within numerous human tissues including brain, liver, and various tumours. 
In these tissues, MALDI IMS has detected sub-classes of phospholipids and sphingolipids 
(SP), such as PCs, PIs, and gangliosides, which are known to influence cell function and 
Lipid Category Product Ion 
m/z 
Product Ion Identity 

























survival82. As such, detection of these lipids within a sample can improve our 
understanding of molecular pathways occurring within the sample.  
 An interesting application of MALDI IMS is for the elucidation of regional lipid 
abnormalities within a tissue sample, as shown by the detection of lipid disturbances in 
pathological tissues such as stroke injuries60. This application of MALDI IMS allows for in 
situ detection, visualization, and quantification of multiple lipid species within a sample, 
allowing for a lipidomic-level approach to identifying differences between pathological 
regions and adjacent healthy regions within a single sample. Such an approach can be 
used for either experimental investigation or diagnostically. Work within this thesis will 
focus on the use of MALDI IMS for experimental investigation of tissues and their lipid 
profiles. The investigative application of MALDI IMS for distinguishing regional lipid 
abnormalities has previously identified abnormalities in diverse lipid classes such as PCs, 
PIs, PEs, and SP. These studies enhance our knowledge of the molecular mechanisms 
that underlie pathologies and provide novel treatment avenues by identifying 
dysregulated lipids that may be targeted to ameliorate disease progression. 
1.4.10 Tissue preservation and MALDI IMS 
 Post-mortem tissue preservation is a critical step to maintain morphological and 
molecular fidelity. These post-mortem alterations, which begin to occur within minutes, 
are most commonly prevented by chemical-fixation with formalin, formaldehyde, or 
paraformaldehyde which prevent post-mortem deterioration, in part, by cross-linking 
proteins to prevent their enzymatic activity88. Chemical-fixation techniques are commonly 
used due to the ease of the preservation protocol and samples not requiring expensive 
cold storage88. As such, robust tissue banks containing chemically-fixed samples with 
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clinical associations have been developed for post-mortem analysis. However, the gold-
standard tissue for MALDI MS has long been fresh-frozen tissue, tissue which is snap-
frozen soon after extraction58,89. Indeed, MALDI MS was previously believed to be 
incompatible with formalin-fixed tissue, largely due to fixation causing the cross-linking of 
proteins and the concerns that fixatives inhibit the detection of lipid molecules58,89. While 
fixatives may inhibit the detection certain lipid classes, such as PEs, recent studies have 
demonstrated that detection of both proteins and lipids from formalin-fixed archive tissue 
is possible with MALDI MS58,89,90. As such, numerous archived formalin-fixed clinically-
relevant tissue samples can now be investigated using MS to elucidate molecular 





Lipids play a critical and dynamic role in regulating cell function and survival. Lipid 
abnormalities observed in various pathologies, such as AD, stroke, cancers, and multiple 
sclerosis, are now known to play a role in disease progression. Whilst lipid abnormalities 
have been observed in some CNS diseases, the technical limitation of lipid detection in 
clinically-relevant formalin-fixed human archival tissue has prevented a greater 
understanding of specific lipid species alterations. MALDI IMS is a molecular imaging 
technique that permits untagged, in situ quantification and visualization of a variety of 
molecules, including multiple lipid classes. To our knowledge, MALDI IMS has never 
previously been applied to distinguish regional lipid abnormalities within MRI-defined 
formalin-fixed post-mortem human brain tissue. Combining current clinically relevant 
imaging techniques, such as MRI, and lipidome analysis with MALDI IMS will permit the 
identification of regional lipid abnormalities associated with pathologies. By elucidating 
regional lipid abnormalities, we will better understand clinically observable neurological 
features, disease mechanisms, and progression, as well as provide novel lipid-based 
targets for therapeutic intervention. 
1.6 Aim and Hypothesis 
 Aim: Investigate the application of MALDI IMS for unbiased, shotgun-style 
investigation of neuroanatomical-specific lipid abnormalities within MRI-defined, post-
mortem, formalin-fixed human CNS tissue. 
 Hypothesis: Lipid abnormalities exist within pathological white matter regions 
identified using post-mortem T2-weighted FLAIR MRI, and MALDI IMS can resolve these 
abnormalities relative to adjacent normal-appearing white matter. 
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CHAPTER 2: METHODS 
2.1 Specimen Selection for MRI Imaging 
Specimen for MRI imaging were chosen based on neuropathological findings 
documented by a certified Neuropathologist at autopsy. Intact brains were obtained from 
a bank of samples that had been stored in 10% neutral buffered formalin for up to 15 
years following previous neuropathological examination. One coronal slice from the 
frontal lobe of each specimen was selected for imaging. The final selection for MRI 
imaging included 20 specimens. Demographic data for the 20 specimens can be found in 
Supplementary Table 1. 
2.2 MRI Brain Imaging 
All scans were performed at Robarts Research Institute’s Centre for Functional 
and Metabolic Mapping on a MAGNETOM 7T MRI Scanner (Siemens).  Coronal slices of 
fixed tissue from the frontal lobes of the brain were removed from formalin and immersed 
in Galden HT-270 perfluorinated fluid (Kurt J Lesker Company, Vaughan, ON, Canada). 
5 coronal sections were scanned simultaneously using a custom-made stacking device 
until coronal sections from all 20 specimens were scanned. The stacking device was 
secured into the head coil apparatus for scanning. Structural MRI images were acquired 
in the coronal orientation with the following sequences: 3D T1-weighted MPRAGE (1 mm 
slice thickness, TR/TE=3000/1.72 ms, flip angle =90,  FOV= 160 x 126 mm , in-plane 
resolution of 0.7 x 0.7 mm), 3D T2-weighted SPACE sequence (1mm slice thickness, 
TR/TE=2500/349 ms, flip angle= 90 FOV = 160 x 120 mm, in plane resolution of 0.5 x 0.5 
mm) and 3D FLAIR sequence (1mm slice thickness, TR/TE/T1=8000/205/1600 ms, flip 




2.3 Specimen Selection for MALDI TOF IMS Scanning 
PvWMHs from the cohort of MRI-scanned specimens were qualitatively evaluated 
using a modified version of the Fazekas’ rating scale91. Eleven brain specimens were 
selected for MALDI TOF IMS imaging that met the MRI-criteria for “moderate pvWMH”, 
which involved a lesion that extended greater than 1/3 of the distance between the edge 
of the ventricle and the cortex. Nine of these brain specimens had bi-lateral moderate 
periventricular WMHs, the remaining two brain specimens were scored as moderate 
periventricular WMH for only one hemisphere. As such, a total of 20 distinct moderate 
pvWMHs from 11 brain specimens were selected for MALDI TOF IMS scanning. These 
specimens represent a heterogenous group with neuropathological diagnoses of 
Alzheimer’s disease and/or cerebrovascular disease. Remaining specimens from the 
MRI-scanned cohort were excluded due to an evaluation of less than or more than 
“moderate pvWMH” on the modified Fazekas’ ratings scale.  
2.4 Tissue blocking 
Tissues containing periventricular white matter were sampled for tissue selection 
based on MRI findings. Tissue blocks were obtained from brain tissue that included the 
moderate pvWMH, subcortical white matter and cortical tissue. Block were stored in 10% 
neutral buffered formalin prior to processing. The anatomy of the cortex and subcortical 
structures was used to correctly match the tissue to the corresponding MRI image. 
2.5 Tissue Sectioning and Mounting 
Formalin-fixed non-embedded tissue blocks were sectioned at 10 µm thickness 
using a Cryostar NX50 cryostat (Thermo-Fisher Scientific, Toronto, ON, Canada) at -
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25oC. Tissue sections were then thaw-mounted to electrically conductive indium-tin-oxide 
coated slides (Hudson Surface Technology Inc., Old Tappan, NY, USA). 
2.6 Ammonium Formate Wash 
Ammonium formate (AF) washes were performed to enhance lipid signal from 
formalin-fixed tissue as previously described58. 
2.7 Matrix Sublimation 
Mounted tissue sections were placed into a sublimation apparatus (Chemglass) 
for sublimation with either DAN matrix (Sigma-Aldrich, Oakville, ON, Canada) for negative 
ion mode scans or DHB matrix (Alfa Aesar, Haverhill, MA, USA) for positive ion mode 
scans. Assembly of apparatus and sublimation of DAN57 and DHB92 was performed as 
previously described. 
2.8 MALDI-TOF-IMS 
MALDI TOF IMS was performed using a Sciex 5800 TOF/TOF system, MALDI 
TOF/TOF (Sciex, Framingham, MA, USA) equipped with a 349 nm Nd:YLF OptiBeam 
On-Axis laser using a laser pulse rate of 400 Hz as previously described58. Reflectron 
negative scans were conducted from m/z 450-1000 and m/z 1000-2000. Reflectron 
positive scans were conducted from m/z 450-1000. TOF TOF Series Explorer (Sciex) and 
Data Explorer (Sciex) software were used for data acquisition and processing, 
respectively. 
2.9 Image and Data Analysis 
MALDI IMS data was visualized using TissueView software (Sciex). Manual 
selection of Region of Interests (ROIs) in white matter that appeared normal on MRI 
(NAWM), and periventricular white matter that appeared hyperintense with MRI (pvWMH) 
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was performed through co-visualization of MALDI TOF IMS images and reference MRI 
scans. Average mass spectra per ROI were then simultaneously generated for each ROI. 
Mass peaks were acquired from each mass spectra based on our established criteria of 
a minimum signal-to-noise ratio (SNR) >3. Mass peaks that did not meet the SNR criteria 
were omitted. Mass peaks were assessed for consistent detection (>80%) in scans from 
all 21 tissue blocks. Mass peaks which were consistently detected in >80% of scans were 
carried forward for statistical analysis. Intensity values corresponding to the monoisotopic 
peak of consistently detected mass peaks were isolated for intrasubject comparison.  
2.10 Identification of Lipid Ions by Searching Experimental m/z in LMISSD and 
SwissLipids 
Identification of mass peaks was primarily conducted by using experimental m/z 
values to interrogate the LIPID Metabolites and Pathway Strategies (MAPS) In Silico 
Structural Database (LMISSD)93. A second independent database, SwissLipids, was 
interrogated using the same approach. Database searches were conducted with the 
following parameters: 
Experimental m/z searches of mass peaks detected in negative ion mode: 
 Mass Tolerance (m/z): ± 0.1 
 Ion Adducts: [M-H]- 
Experimental m/z searches of mass peaks detected in positive ion mode: 
 Mass Tolerance (m/z): ± 0.1 




LMISSD resource available at: 
https://www.lipidmaps.org/resources/databases/lmissd/search.php. 
SwissLipids resource available at: 
https://www.swisslipids.org/#/advanced 
2.11 Identification of Previously Unidentified Mass Peaks by MALDI TOF Tandem 
Mass Spectrometry 
To assist the identification of select mass peaks in negative low-range, tissue was 
prepared for MALDI TOF IMS imaging and subjected to tandem mass spectrometry 
(MSMS) in the Sciex 5800 TOF/TOF system, MALDI TOF/TOF (Sciex, Framingham, MA, 
USA). Reflectron negative mode was used to generate negative MSMS from parent 
peaks in the m/z 450-1000 range and m/z 1000-2000 range. Reflectron positive mode 
was used to generate positive MSMS from parent peaks in the m/z 450-1000 range. 
Reflectron modes were externally calibrated at 50 ppm mass tolerance and internally at 
10 ppm mass tolerance. TOF/TOF Series Explorer (Sciex) and Data Explorer (Sciex) 
software were used for data acquisition and processing respectively. MSMS product ion 
spectra were visualized using LipidBlast85. MSMS search criteria were set using the 
previously described recommendations85. Manual interrogation of MSMS product ion 
spectra was performed to identify the presence of characteristic lipid class peaks.  
2.12 Statistical Analysis 
Intrasubject lipid comparison was conducted by comparing monoisotopic intensity 
values of NAWM to pvWMH for every mass peak that was detected in >80% of the 21 
tissue blocks scanned. Paired two-tailed Student’s t-tests were used to test for 
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significance between NAWM and pvWMH for each mass peak. A p-value of <0.05 was 
considered significant. N indicates biological N-value. 
CHAPTER 3: RESULTS 
3.1 Lipid Detection Metrics 
Analysis of MALDI IMS spectra from all 21 tissue blocks yielded a total of 87 unique 
ions in negative ion high-range scans, 125 unique ions in negative ion low-range scans, 
and 96 unique ions in positive ion low-range scans (Table 2). These mass peaks were 
then assessed between for consistent detection in all specimens (observed in >80% of 
the 21 tissue blocks). A total of 30 ions from negative ion high-range scans, 41 ions from 
negative ion low-range scans, and 45 ions from positive ion low-range scans were carried 
forward for statistical evaluation. 
Table 2. MALDI IMS of formalin-fixed post-mortem human white matter consistently 
detected 116 ion species. Peaks detected in mass spectra generated using a Sciex 
5800 TOF/TOF system, from post-mortem human brain tissue using Reflectron negative 
and positive ion modes with DAN and DHB matrices, respectively. 
 
Scan Mode Total Ion Species Ion Species with >80% 
Detection 
Negative ion m/z 1000-2000  87 30 
Negative ion m/z 450-1000  125 41 




Figure 4. Annotated MALDI-TOF mass spectra of post-mortem human white matter. 
Representative white matter mass spectra annotated with tentative lipid ion identities for 
mass peaks that were significantly altered between pvWMH and NAWM. A) Negative ion 
mass spectrum m/z 1000-2000 obtained from tissue sublimated with 1,5-DAN matrix in 
negative ion detection mode. B) Negative ion mass spectrum m/z 450-1000 obtained from 
tissue sublimated with 1,5-DAN matrix in negative ion detection mode. C) Positive ion 
mass spectrum m/z 450-1000 obtained from tissue sublimated with 2,5-DHB matrix in 
positive ion detection mode. 
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3.2 Negative ion MALDI IMS scans detect regional lipid abnormalities within 
pvWMHs – m/z 1000-2000 Range 
Intrasubject comparison of negative ion spectra at m/z 1000-2000 elucidated 
significant differences in 10 of the 30 mass peaks assessed (Fig. 5, Table 1). An increase 
of monoisotopic peak intensities in the pvWMH relative to NAWM were observed for the 
ion species occurring at m/z = 1572.9 and 1544.9 (Fig. 5). Decreases in monoisotopic 
peak intensities were observed for the ions at m/z = 1303.1. 1288.1, 1170.0, 1153.0, 
1135.8, 1133.8, 1110.8, and 1108.8 (Fig. 5).  
Identities were assigned to lipid ions by searching two independent lipid 
databases, LMISSD and SwissLipids, with experimentally generated m/z values using the 
parameters described in our methods (Fig. 5, Table 3). This method for identity 
assignment often yielded multiple tentative identities that were indistinguishable at MS1, 
as such, on-tissue MALDI MSMS was performed to assist in lipid class assignment. We 
attempted to generate MALDI MSMS product ion spectra from all significantly different 
mass peaks, however, not all mass peaks produced conclusive MALDI MSMS product 
ion spectra. MALDI MSMS product ion spectra were manually interrogated for the 
presence of characteristic fragments to assist confident assignment of lipid class, a similar 
approach taken by previous untargeted MALDI MS investigations87. Detailed structural 
characterizations of select product ion spectra, such as from the precursor occur at m/z 
= 1544.9 (Fig. 6), were performed, however complete characterization of all species is 
beyond the scope of the current investigation. 
 All product ion spectra generated from precursors detected in negative high-range 
scans, excluding the precursor ions occurring at m/z = 1572.9 and 1544.9, produced 
fragment ions at either m/z = 153, 171, or both (Table 3). These product ion fragments 
32 
 
correspond to [glycerol phosphate-H2O-H]- and [glycerol phosphate-H]-, respectively, as 
such, precursor ions that fragment to produce these product ions can be unambiguously 
identified as glycerophospholipids (Table 1, 3). 
Following unambiguous confirmation that all significantly altered species, 
excluding the precursor ions occurring at m/z = 1572.9 and 1544.9, were in fact 
glycerophospholipids, lipid class assignment was attempted by manually assessing 
product ion spectra for the presence of characteristic fragments. Table 1 provides a 
summary of previously published characteristic lipid fragments that may be observed in 
negative mode product ion spectra generated from major lipid classes detectable using 
MALDI IMS in human brain tissue30,94–96 
The product ion spectra of the precursor ions occurring at m/z = 1572.9 and 1544.9 
both contained prominent fragment peaks at m/z = 290.0, a characteristic fragment of 
gangliosides which corresponds to [N-acetylneuraminic acid-H]- (Table 1, 3)58. Detailed 
structural characterization of the precursor ion occurring at m/z = 1544.9 was performed 
using the MALDI MSMS product ion spectra (Fig. 6). The presence of the [N-
acetylneuraminic acid-H]- fragment supports the confident assignment of 
monosiayloganglioside (GM) species [GM1 38:1-H]- (d20:0) and [GM1 36:1-H]- (d18:0) to 
m/z = 1572.9 and 1544.9, respectively, as has been identified in previous publications97. 
Our experimental m/z value for the species occurring at m/z 1303.1 failed to 
provide reliable identification in either lipid database used. Analysis of the MALDI MSMS 
product ion spectra from this peak was inconclusive, possibly due to the low SNR of the 
precursor. However, product ion peaks were observed at m/z 97.0 and 171.0, known 
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phospholipid headgroup fragments, confirming that the ion occurring at m/z 1303.1 is a 
phospholipid of unknown identity. 
 
Figure 5. High range negative ion detection MALDI IMS scans distinguished 
increased and decreased lipid ion intensity in pvWMHs relative to NAWM in post-
mortem human tissue. A) Coronal FLAIR MRI of a post-mortem human brain. Red 
asterisk indicates region identified as a pvWMH. Black box indicates approximate area 
that was dissected for sectioning. Red outline indicates extent of pvWMH. Blue outline 
indicates a region of NAWM. B) H&E. V, Cau, and Ctx indicate ventricle, caudate, and 
cortex, respectively. Scale bar = 5 mm. C) & D) MALDI IMS scans conducted on post-
mortem human brain tissue sublimated with 1,5 DAN matrix. Intensity maps generated 
from (C) [GM1 36:1-H]- and (D) [PI O-68:6-H] -. Scale bars = 5 mm. E) Pseudocoloured 
intensity maps showing the overlay of [GM1 36:1-H]- and [PI O-68:6-H] -. F) 
pvWMH:NAWM fold-change of monoisotopic peak intensity for statistically significant 
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lipids. Data presented as mean(SD). * indicates p<0.05,**p<0.01, ***p<0.001  via two-
tailed Student’s T-Test (n=18-20). 
 
Table 3. Identification of significantly altered lipid ions detected in negative ion 
high-range scans by database interrogation and negative mode on-tissue MALDI 
MSMS in formalin-fixed post-mortem human white matter. Peaks detected in mass 
spectra generated using a Sciex 5800 TOF/TOF system, from DAN-coated post-mortem 
human brain tissue in negative ion mode at m/z 1000 – 2000. Theoretical m/z values and 
identification based on experimental m/z searches in LMISSD and SwissLipids, 






















87.0, 154.0, 290.0, 561.8, 





1303.0667  97.0, 171.0, 435.4, 663.9, 







1288.0513 87.0, 153.0, 171.0, 435.3, 






1169.9988 97.0, 153.0, 171.0, 281.2, 







1152.9863 78.9, 153.0, 171.0, 281.2, 






1135.8073 153.0, 171.0, 255.2, 281.3, 





1133.7919 153.0, 171.0, 226.0, 409.2, 





1110.8079 153.0, 171.0, 401.2, 459.1, 
684.6, 743.9, 783.8, 790.3, 





1108.8065 153.0, 171.0, 417.2, 649.6, 


















Figure 6. On-tissue negative mode MALDI MSMS characterization of the 
precursor peak occurring at m/z 1544.9. On-tissue MALDI MSMS of the peak at m/z 
1544.9 produced fragments characteristic of [GM1 38:1-H]- (d20:0). MSMS product ion 
spectra visualized using LipidBLAST software85. MALDI MSMS was performed at 
described in Methods. GM1 38:1 molecular structure visualized from LMISSD93. 
 
 
3.3 Negative ion MALDI IMS scans detect regional lipid abnormalities within 
pvWMHs – m/z 450-1000 Range 
 Analysis of negative ion scans conducted at m/z 450-1000 revealed differences in 
expression for 11 of 41 consistently detected ion species (Fig. 7, Table 4). Increased peak 
intensity was observed for the ions occurring at m/z = 932.6, 920.6, 916.6, 878.7, 876.7, 
715.6, 644.4, 599.2, 597.2, and 563.3 (Fig. 7). The intensity of the mass peak at m/z = 
647.0 was found to be significantly decreased in WMHs relative to NAWM (Fig. 7).  
Assignment of ion species to significant mass peaks in negative ion low range 
scans was performed by experimental m/z searches in LMISSD and SwissLipids (Table 





4). Similarly to the identification of ion species in the higher range negative ion detection 
mode, on-tissue MALDI MSMS spectra were generated to assist the confident 
assignment of lipid ion identities. We attempted to generate negative ion MSMS spectra 
from all significantly altered precursor species, however, the ion species occurring at m/z 
= 878.7, 876.7, 644.4 failed to generate viable MSMS spectra. Similar to product ion 
spectra generated from high range negative ion precursors, product ion spectra in this 
range showed fragments at m/z = 79, 153, 171 (Table 4). As previously reported, these 
fragments are characteristic fragments of glycerophospholipids, confirming that all altered 
lipid ion species in low range negative ion scans are glycerophospholipids (Table 1, 4). 
Using this strategy, we assigned tentative lipid ion identities to all mass peaks, 





Figure 7. Low range negative ion detection MALDI IMS scans distinguished 
increased and decreased lipid ion intensity in pvWMHs relative to NAWM in post-
mortem human tissue. A) Coronal FLAIR MRI of a post-mortem human brain. Red 
asterisk indicates region identified as a pvWMH. Black box indicates approximate area 
that was dissected for sectioning. Red outline indicates extent of pvWMH. Blue outline 
indicates a region of NAWM.  B) H&E. V, Cau, and Ctx indicate ventricle, caudate, and 
cortex, respectively. Scale bar = 5 mm. C) & D) MALDI IMS scans conducted on post-
mortem human brain tissue sublimated with 1,5 DAN matrix. Intensity maps generated 
from (C) [Hex1Cer 34:0-H]- and (D) the mass peak occurring at m/z 647.0. Scale bars = 
5 mm. E) Pseudocoloured intensity maps showing the overlay of [Hex1Cer 34:0-H]- and 
the mass peak occurring at 647.0 m/z. F) pvWMH:NAWM fold-change of monoisotopic 
peak intensity for statistically significant lipids. Data presented as mean(SD). * indicates 


















[PS 47:6-H]- 932.6386 4.8357 
920.6273 97.0, 119.0, 153.0, 
241.0, 283.0, 327.0, 
419.2, 522.3, 542.3, 
581.2, 727.0, 880.0 
 
[PS 46:5-H]- 920.6386 -12.2719 
916.6389 59.0, 97.0, 119.0, 
124.4, 241.1, 540.4, 
871.2 
 
[ST 44:2-H]- 916.6548 17.3023 
878.6607 N/A [PE 46:4-H]- 878.6644 -4.2462 
876.6714 N/A [PE O-47:5-H]- 876.6852 -15.7183 
716.5751 79.0, 153.0, 171.0, 
226.0, 281.2, 419.3, 
505.4 
[Hex1Cer 34:0-H]- 716.5682 9.6516 
646.9677 N/A Unidentified N/A N/A 




[PE 29:2-H]- 644.4297 8.4307 
599.2397 79.0, 140.0, 153.0, 
171.0, 255.2, 283.3, 
419.4, 535.0 
 
 [PI 16:0(Ke)-H]- 599.2474 -12.8194 
597.2254 79, 97, 153, 255.2, 
283.3, 419.3, 535.5 
 
 [PI 16:1(Ke)-H]- 597.2318 -10.6742 
563.2596 79.0, 153.0, 171.0, 







Table 4. Identification of significantly altered lipid ions detected in negative ion low-
range scans by database interrogation and negative mode on-tissue MALDI MSMS 
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in formalin-fixed post-mortem human white matter. Peaks detected in mass spectra 
generated using a Sciex 5800 TOF/TOF system, from DAN-coated post-mortem human 
brain tissue in negative ion mode at m/z 450 – 1000 m/z. Theoretical m/z values and 
tentative IDs based on experimental m/z searches in LMISSD, SwissLipids, 
complemented with manual interrogation of on-tissue MALDI MSMS as described in 
Methods. 
 
3.4 Regional phosphatidylcholine and sphingomyelin abnormalities detected 
using positive ion MALDI IMS scans within pvWMHs 
 Spectra generated at m/z 450-1000 in positive ion mode showed significant 
increases in the four ion species detected at m/z = 764.8, 734.7, 725.6, and 703.6 (Fig. 
8), with a simultaneous decrease in the six ion species detected at m/z = 848.7, 774.7, 
772.7, 746.7, 550.4, and 504.4 (Fig. 8).  
Identification of previously unidentified positive ion mass peaks was performed by 
experimental m/z searches of the LMISSD and SwissLipids databases (Table 5). On-
tissue MALDI MSMS was also conducted in positive ion detection mode (Table 5). Using 
this approach, we identified all significantly different mass peaks detected in positive 
mode scans, except for the mass peaks detected at m/z = 764.8 and 734.7 (Fig. 8, Table 
5).  
Manual interrogation of positive ion product spectra generated using on-tissue 
MALDI MSMS revealed the presence of a characteristic PC and SM headgroup 
fragment98, m/z 184 = [phosphocholine+H]+, in all product spectra (Table 5). The 
presence of this headgroup fragment in all product spectra generated from species 
detected in positive mode confirms that positive mode MALDI IMS scans of white matter 
tissue abundantly detects PC and SM species99. Due to the presence of a product ion 
fragment at m/z 184, database searches in LMISSD and SwissLipids for species detected 
in positive mode scans were limited to lipid species which contain a phosphocholine in 
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their headgroup, an approach which dramatically reduced the number of potential 
identities. 
 
Figure 8. Low range positive ion detection MALDI IMS scans distinguished 
increased and decreased lipid ion intensity in pvWMHs relative to NAWM in post-
mortem human tissue. A) Coronal FLAIR MRI of a post-mortem human brain. Red 
asterisk indicates region identified as a pvWMH. Black box indicates approximate area 
that was dissected for sectioning. Red outline indicates extent of pvWMH. Blue outline 
indicates a region of NAWM. B) H&E. V, Cau, and Ctx indicate ventricle, caudate, and 
cortex, respectively. Scale bar = 5 mm. C) & D) MALDI IMS scans conducted on post-
mortem human brain tissue sublimated with 2,5 DHB matrix. Intensity maps generated 
from the mass peak occurring at (C) [SM 34:1+H]+.  and (D) [PC O-34:3+Na]+. Scale bars 
= 5 mm. E) Pseudocoloured intensity maps showing the overlay of [SM 34:1+H]+  and PC 
O-34:3+Na]+. E) pvWMH:NAWM fold-change of monoisotopic peak intensity for 
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statistically significant lipids. Data presented as mean(SD) * indicates p<0.05,**p<0.01 
via two-tailed Student’s T-Test (n=16-20). 
 
 
Table 5. Identification of significantly altered lipid ions detected in positive ion low-
range scans by database interrogation and positive mode on-tissue MALDI MSMS 
in formalin-fixed post-mortem human white matter. Peaks detected in mass spectra 
generated using a Sciex 5800 TOF/TOF system, from DHB-coated post-mortem human 













39.0, 86.1, 104.1, 163.0, 
184.1, 224.0, 454.3, 480.2, 
542.6, 659.4, 705.8, 763.9, 
792.8, 793.7 
 
[PC O-40:3+Na]+ 848.6504 84.8524 
774.6687 39.0, 86.1,184.1, 198.1, 











764.7509 184.0, 369.3, 410.9, 468.9, 
561.2, 632.6, 697.1, 710.5 
 
Unidentified N/A N/A 






734.7445 184.0, 341.4, 419.3, 537.4, 
579.4, 608.9, 639.3, 648.5 
 
Unidentified N/A N/A 
725.6122 37.8, 169.1, 184.0, 307.2, 
400.2, 430.8, 567.1, 670.4 
 
[SM 36:4+H]+  725.5592 73.047106 
703.6105 171.1, 184.1, 425.2, 520.2, 
525.5, 599.3, 634.4, 652.4 
 
[SM 34:1+H]+ 703.5749 50.5987 




[PC or LPC+H 
H]+  
550.3867 39.0634 
504.3605 60.0, 104.1, 184.0, 342.8, 







tentative IDs based on experimental m/z searches in LMISSD, SwissLipids and manual 
interrogation of on-tissue MALDI MSMS product ion spectra. 
CHAPTER 4: DISCUSSION 
In this study, we demonstrate for the first time the use of MALDI IMS to identify 
lipid abnormalities of MRI-defined pvWMHs within formalin-fixed, human brain tissue. As 
previously shown, MALDI of DAN or DHB-coated tissue was effective for the respective 
negative or positive ionization of lipids92. MALDI IMS scans conducted in negative mode 
m/z 450 – 2000 and positive mode m/z 450-1000 permitted the consistent detection 
(>80% of the 21 tissue blocks) of 116 unique ion species across the three scan modes. 
Analysis of consistently detected mass peaks elucidated intrasubject differences in lipid 
expression between NAWM and pvWMHs for 31 lipid ion species. Lipid profile alterations 
were bi-directional, representing increases in 16 mass peaks and decreases in 15 mass 
peaks in pvWMHs relative to NAWM. Experimental m/z searches in lipid databases, 
LMISSD and SwissLipids, and manual interrogation of MALDI MSMS product ion spectra, 
permitted the assignment of lipid ion identities to 27 of the 31 significantly altered mass 
peaks. This investigation has exhibited the novel use of MALDI IMS for comparative lipid 
profile characterization of healthy and pathological tissue in clinically relevant, formalin-
fixed, human brain tissue. 
The consistent detection of 116 mass peaks amongst all tissue samples 
corresponding to positive and negative ions at m/z 450 – 2000 demonstrates the potential 
of MALDI IMS for broad, untagged approach to lipid investigations. Although these 
consistently detected species do not represent the totality of lipids that are present in 
human white matter, as some lipid species may not ionize in the presence of either DAN 
or DHB matrix, it does represent a broad profile of the lipid species present in human 
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white matter. This application is better suited for a ‘rule-in’ rather than ‘rule-out’ approach 
due to the aforementioned poor ionization of certain lipid species, or ion suppression from 
readily-ionized molecules such as PC species in positive ion mode99. This ‘rule-in’ 
approach is important to consider when assessing lipid abnormalities in formalin-fixed 
tissue as formalin is known to degrade the signal of phosphoethanolamines, thus making 
phosphoethanolamine abnormalities less apparent100. 
Gangliosides are ubiquitously expressed lipids that are highly enriched in neural 
tissue101. Gangliosides are an integral membrane component of many cell populations 
within the CNS, where they play critical roles in the structure of the plasma membrane, 
as well as influencing the localization of proteins within the plasma membrane102. 
Ganglioside abnormalities have previously been associated with neurodegenerative 
diseases such as Alzheimer’s disease, stroke, and multiple sclerosis102,103. Interestingly, 
we observed an increase in the intensity of mass peaks associated with negative ions of 
GM1 36:1 (18:0) and GM1 38:1 (d20:0) in pvWMHs relative to NAWM. The GM1 
ganglioside species have previously been associated with neuroprotective effects102. 
Numerous mechanisms for the neuroprotective effects of GM1 species have been 
proposed, including the inhibition nitric oxide synthase activity104, prevention of glutamate 
toxicity105, and influencing the activity of protein receptors via membrane microdomain 
organization106.  Therefore the effects of GM1 species in pvWMHs are likely multimodal, 
varying depending on the cell population in-question102. Thus, further work is required to 
elucidate what cell population, or populations, are responsible for the observed increase 
of GM1 in pvWMHs. 
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An interesting observation in the imaging data is that some lipid species elevated 
in the pvWMH were also elevated in the adjacent caudate. Our current understanding of 
this observation is limited, however, a proposed cause of this may be leakage of biological 
macromolecules from vicinal regions into the pvWMH during the development of the 
pvWMH. Factors such as localized tissue rarefaction and edema in the pvWMH may play 
a role in the leakage of molecules from vicinal regions, and vice-versa13,22. PvWMHs are 
known to be progressive, however, molecular mechanisms behind the spreading 
pathology of pvWMHs remain somewhat limited107. Whilst speculative, if this leakage 
phenomenon were confirmed, this could suggest a potential molecular mechanism for the 
propagation of pvWMHs into adjacent regions. 
Confident assignment of lipid ion identity is a critical aspect of any investigation of 
lipid abnormalities. In the current study, assignment of lipid identity was attempted by 
searching experimental m/z values in two independent databases, LipidMAPS and 
SwissLipids, and assisted by manual interrogation of product ion spectra generated by 
on-tissue MALDI MSMS. A limitation currently facing the use of MALDI IMS for analysis 
of formalin-fixed tissue is the difficulty in assigning ion species identities to mass peaks 
using MSn. MS1 is unable distinguishing structural isomers, thus demonstrating the need 
for MSMS-based identification. Manual interrogation of MSMS spectra for the presence 
of characteristic peaks has previously been used to assist lipid identity assignment87. 
However, this technique is not feasible for complete structural characterization of all 
significantly altered species identified in pvWMHs in the current study. Other publications 
in the field of lipid analysis have noted that the popular use of MALDI mass spectrometry 
as a tool for protein analysis has contributed to the development of software for the 
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identification of proteins, however, software for lipid identification is notably trailing108,109. 
We believe future studies using MALDI IMS for lipid detection would benefit from the 
development of species-specific and tissue-specific lipid identification databases. 
Conclusions 
In conclusion, we have demonstrated the viability of using MALDI IMS for a broad, 
untagged approach to lipid detection in archived, formalin-fixed, post-mortem human 
brain tissue. This approach permitted the consistent detection of 116 distinct ion species 
in 21 tissue blocks from 11 brains. We have shown the application of MALDI IMS for 
resolving intrasubject differences in lipid expression by detecting bidirectional differences 
in mass peak intensity between pvWMHs and adjacent NAWM. By interrogating two 
independent lipid databases, LipidMAPS and SwissLipids, as well as conducting on-
tissue MALDI MSMS, we assigned tentative lipid ions identities to 27 mass peaks. 
Interestingly, two observed differences were increases of the neuroprotective 
gangliosides GM1 36:1 (d18:0) and GM1 38:1 (d20:0) in pvWMHs relative to NAWM. 
Further investigation is required to identify what cell population is responsible for the 
observed elevation in GM1 species and the biological ramifications of elevated GM1 in 
WMHs. Assignment of lipid ion identities to the remaining mass peaks represents a 
limitation of lipid analysis in formalin-fixed non-embedded post-mortem human tissue, 
however, we believe that advancements in lipid-related software will continue to 
contribute to high-throughput bioinformatic-scale lipid analysis using MALDI IMS. In 
summary, this study demonstrates the potential of MALDI IMS for the purpose of spatial-
specific lipid quantification in MRI-defined, formalin-fixed, post-mortem human tissue and 
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n Age ± SD Male Sex (%) Fixation Length 
(months) ± SD 
Normal 5 69.4 ± 12.9 2 (40%) 155 ± 3.8 
AD 5 75.4 ± 5.5 3 (60%) 136 ± 40.1 
CVD 5 72.6 ± 13.2 4 (80%) 134 ± 39.4 
AD + CVD 5 82.2 ± 5.8 1 (20%) 160 ± 3.1 
 
Supplementary Table 1: Demographic data from specimen selection including 
neuropathological group, age at time of death, sex and fixation lengths (months since 
date of autopsy). 
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